Photo: Courtesy of Eli Lilly
24 March 2016Big Pharma
UK Supreme Court to hear Alimta patent dispute
The UK Supreme Court has said it will hear a patent dispute between Eli Lilly and Allergan centring on cancer drug Alimta (pemetrexed disodium).
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
15 February 2016 Eli Lilly has lost the latest round of its patent battle with Allergan centring on the lung cancer drug Alimta.
Big Pharma
8 March 2016 In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports.
Editor's picks
Editor's picks
Big Pharma
15 February 2016 Eli Lilly has lost the latest round of its patent battle with Allergan centring on the lung cancer drug Alimta.
Big Pharma
8 March 2016 In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports.
Big Pharma
15 February 2016 Eli Lilly has lost the latest round of its patent battle with Allergan centring on the lung cancer drug Alimta.
Big Pharma
8 March 2016 In February the English High Court ruled that Actavis had not indirectly infringed a patent owned by Eli Lilly directed to cancer drug Alimta. David Read of Bartle Read reports.